AbCellera Biologics Inc. (NASDAQ:ABCL) has a beta value of 0 and has seen 1,447,704 shares traded in the last trading session. The company, currently valued at $10.75 Billion, closed the last trade at $39.95 per share which meant it gained $3.36 on the day or 9.18% during that session. The ABCL stock price is -80% off its 52-week high price of $71.91 and 9.21% above the 52-week low of $36.27. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.42 Million shares traded. The 3-month trading volume is 1.74 Million shares.
The consensus among analysts is that AbCellera Biologics Inc. (ABCL) is a Buy stock at the moment, with a recommendation rating of 0. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 5 have rated it as a Hold, with 5 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $1.36.
AbCellera Biologics Inc. (NASDAQ:ABCL) trade information
Wall Street analysts have a consensus price target for the stock at $51.4, which means that the shares’ value could jump 28.66% from current levels. The projected low price target is $45 while the price target rests at a high of $59. In that case, then, we find that the current price level is +47.68% off the targeted high while a plunge would see the stock lose 12.64% from current levels.
AbCellera Biologics Inc. (ABCL) estimates and forecasts
Earnings growth for 2021 is a modest -857.5%.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.